BRD4 is also linked to Alzheimer's disease in which BRD4 inhibition increases brain cognitive ability. In addition, blocking this protein also prevent the neuro dysfunction caused by brain stroke. That dBET57 disrupted BRD4 function, leading to the downregulation of critical super enhancer-associated genes, resulting in inhibited cancer cell growth and induced apoptosis. Recently using experimental methods, the possibility of using dBET57 as a medicinal agent for neuroblastoma has been discovered . In addition, various clinical trials are being conducted that target BRD4 protein for hematological and solid cancers . This preclinical research has also suggested chemotherapeutic drugs can be used in combination with BET inhibitors. A few kinds of chemotherapeutic medications, such as proteasome inhibitors, tyrosine kinase inhibitors, CDK inhibitors, and immunotherapies, have been found in recent preclinical research as being useful in conjunction with BET inhibitors to improve therapeutic result and circumvent BET inhibitor resistance. Therefore, it is going to be crucial to also design biomarkers to compute the efficacy of these drug blends. Moreover, the identified BET inhibitions have short half-life and need further chemical modification and detained pharmacokinetic and pharmacodynamic evaluation of these compounds will be helpful.